Details for New Drug Application (NDA): 213823
✉ Email this page to a colleague
The generic ingredient in BORTEZOMIB is bortezomib. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the bortezomib profile page.
Summary for 213823
| Tradename: | BORTEZOMIB |
| Applicant: | Baxter Hlthcare Corp |
| Ingredient: | bortezomib |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 213823
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Strength | 3.5MG/VIAL | ||||
| Approval Date: | May 2, 2022 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
